Literature DB >> 8628456

Survival and proliferation of nonneural tissues, with obstruction of cerebral ventricles, in a parkinsonian patient treated with fetal allografts.

R D Folkerth1, R Durso.   

Abstract

BACKGROUND: Since 1985, treatment of idiopathic Parkinson's disease (PD) by surgical transfer of adult or fetal chromaffin tissue or of fetal central neural tissue to the brains of afflicted patients has been attempted, with variable clinical results. Neuropathologic studies of the status of these transplants are few and show wide variation in degree of graft survival.
METHODS: We report the case of a 52-year-old man, who, 23 months earlier, received both intrastriatal implantation and intraventricular infusion of tissues derived from fetuses of 15 to 16 weeks and 5 to 6 weeks gestational age. Clinical improvement, as measured by increased amounts of "on" time with reduced levodopa requirements, seemed to occur over the subsequent months. He died suddenly at home after a several-hours interval of progressive lethargy and breathing difficulties.
RESULTS: At autopsy, the diagnosis of PD was confirmed. Intrastriatal graft sites were identified, but contained no viable neurons; astrogliosis, focal microgliosis, and mixed inflammatory response, suggesting allograft rejection, were present. Surprisingly, the intraventricular tissues survived and showed ectodermal and mesenchymal, but no neural, differentiation, as well as cellular response; the left lateral and fourth ventricles were filled completely by this proliferated tissue.
CONCLUSIONS: By intraventricular infusion, tissues from early-gestation sources can engraft successfully, grow, and survive for at least 23 months in the brain of a PD patient. However, contamination by, or differentiation into, nonneural tissues can occur, can lead to proliferation of tissues within ventricular spaces, and may result in ventricular obstruction. Grafts, whether intraventricular or intraparenchymal, are capable of inciting host responses, which in turn may limit their long-term survival. Finally, post-transplant clinical improvement in symptoms of PD may be unrelated to survival of engrafted neurons.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8628456     DOI: 10.1212/wnl.46.5.1219

Source DB:  PubMed          Journal:  Neurology        ISSN: 0028-3878            Impact factor:   9.910


  9 in total

1.  Unilateral transplantation of human primary fetal tissue in four patients with Huntington's disease: NEST-UK safety report ISRCTN no 36485475.

Authors:  A E Rosser; R A Barker; T Harrower; C Watts; M Farrington; A K Ho; R M Burnstein; D K Menon; J H Gillard; J Pickard; S B Dunnett
Journal:  J Neurol Neurosurg Psychiatry       Date:  2002-12       Impact factor: 10.154

Review 2.  The design of clinical trials for cell transplantation into the central nervous system.

Authors:  Pierre Cesaro
Journal:  NeuroRx       Date:  2004-10

3.  A patient with Huntington's disease and long-surviving fetal neural transplants that developed mass lesions.

Authors:  C Dirk Keene; Rubens C Chang; James B Leverenz; Oleg Kopyov; Susan Perlman; Robert F Hevner; Donald E Born; Thomas D Bird; Thomas J Montine
Journal:  Acta Neuropathol       Date:  2008-12-05       Impact factor: 17.088

4.  Human pluripotent stem cell therapy for Huntington's disease: technical, immunological, and safety challenges human pluripotent stem cell therapy for Huntington's disease: technical, immunological, and safety challenges.

Authors:  Camille Nicoleau; Pedro Viegas; Marc Peschanski; Anselme L Perrier
Journal:  Neurotherapeutics       Date:  2011-10       Impact factor: 7.620

5.  Purified mouse dopamine neurons thrive and function after transplantation into brain but require novel glial factors for survival in culture.

Authors:  A E Donaldson; C E Marshall; Ming Yang; S Suon; Lorraine Iacovitti
Journal:  Mol Cell Neurosci       Date:  2005-09       Impact factor: 4.314

6.  On the Road from Phenotypic Plasticity to Stem Cell Therapy.

Authors:  Lorraine Iacovitti
Journal:  J Neurosci       Date:  2021-05-06       Impact factor: 6.167

7.  Large-sized Fetal Striatal Grafts in Huntington's Disease Do Stop Growing: Long-term Monitoring in the Florence Experience.

Authors:  Mario Mascalchi; Stefano Diciotti; Marco Paganini; Andrea Bianchi; Andrea Ginestroni; Letizia Lombardini; Berardino Porfirio; Renato Conti; Nicola Di Lorenzo; Gabriella Barbara Vannelli; Pasquale Gallina
Journal:  PLoS Curr       Date:  2014-08-04

8.  Transplantation of Deprenyl-Induced Tyrosine Hydroxylase-Positive Cells Improves 6-OHDA-Lesion Rat Model of Parkinson's Disease: Behavioral and Immunohistochemical Evaluation.

Authors:  Maryam Haji Ghasem Kashani; Mohammad Taghi Ghorbanian; Leili Hosseinpour
Journal:  Cell J       Date:  2013-05-05       Impact factor: 2.479

9.  The long-term safety and efficacy of bilateral transplantation of human fetal striatal tissue in patients with mild to moderate Huntington's disease.

Authors:  Roger A Barker; Sarah L Mason; Timothy P Harrower; Rachel A Swain; Aileen K Ho; Barbara J Sahakian; Raj Mathur; Sohier Elneil; Steven Thornton; Carrie Hurrelbrink; Richard J Armstrong; Pam Tyers; Emma Smith; Adrian Carpenter; Paola Piccini; Yen F Tai; David J Brooks; Nicola Pavese; Colin Watts; John D Pickard; Anne E Rosser; Stephen B Dunnett
Journal:  J Neurol Neurosurg Psychiatry       Date:  2013-01-23       Impact factor: 10.154

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.